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Background: Cervical cancer, a common cause of death among women, is attributable to human papilloma virus 
(HPV). Human immunodeficiency virus (HIV) infection can potentially alter the incidence of cervical cancer. 
Prophylactic HPV vaccines are a major advance against cervical cancer. Epidemiological research on HPV and cervical 
cancer is therefore justified. 
Objective: To determine the impact of HIV and HPV co-infection on the HPV genotype distribution and cervical lesion 
grade in Tigoni, Kenya.  
Methodology: This was a cross-sectional study. Women aged 25 to 60 years were invited for cervical cancer and HIV 
screening. HPV typing was done by PCR on residual cervical samples after cytology reporting. 
Results: Of 438 samples, 140 (31.96%) were positive for at least one type of HPV. The most frequent HPV types were 
16, 56, 53, 35, and 39. When co-infection with HIV was examined, 37 (32.5%) were HPV-/HIV+, 63 (19.4%) were 
HPV+/HIV-, 77 (67.5%) were HPV+/HPV+ (p<0.0001). High risk (HR)-types were the more frequent across all 
positive samples; HR-HPV+/HIV+ were 43 (37.7%), (p<0.0001).  
Conclusion: HIV infection was a significant risk factor in HPV infection with 65.5% of cases being both HPV and HIV 
infected. Over 77% of those individuals who had a CIN III or greater were HPV positive. HR-HPV types were found 
across all diagnostic categories in the cases that had a cervical tissue biopsy with HPV type 16 being the most 
dominant type, particularly in high grade lesions. 
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1. Introduction 
Cervical cancer is an important global public health 
problem and a common cause of death among women, 
and it is attributable to human papillomavirus (HPV) 
(Walboomers et al, 1999; Parkin et al, 2008). In a large 
series of invasive cervical cancer from around the 
world, HPV-DNA was detected in 99.7% of the tumors, 
leading to the conclusion that HPV was a necessary 
cause of cervical cancer (Bosch et al, 1995; Walboomers 
et al, 1999; Bosch et al, 2007).  The identification of 
HPV’s role in cervical cancer has led to important 
advances in primary prevention through vaccination 
and diagnosis through HPV detection (Stanley et al, 
2008; Bosch et al, 2008).  However, tangible reduction 
in the incidence of cervical cancer and the impact on 
global public health will probably take decades. As HPV 
types are divergent, efficacy of current vaccines is type-
restricted, and therefore development of the next 
generation of HPV vaccines will require inclusion of 
relevant antigens from several HPV types (Lowy, 2008). 
Geographical profiling of HPV type distribution will be 
important in making vaccines more relevant for target 
populations. 
Most women will be infected with HPV sometime in 
their lifetime. Results from large meta-analyses studies 
indicate that at any given point in time, 10.4% (95% 
confidence interval (CI) 10.2-10.7) of women 
worldwide are positive for cervical HPV DNA (Bosch et 
al, 2008). The prevalence of HPV is higher in less 
developed regions (13.4%; 95% CI: 13.1-13.7) than in 
the more developed regions (8.4%; 95% CI: 8.3-8.6) 
(Bosch et al, 2008). The same studies indicate that 
African women at 22.1% (95% CI: 20.9-23.4) and East 
African women in particular, have the highest HPV 
prevalence rates (31.6%; 95% CI: 29.5-33.8) (Bosch et 
al, 2008). HPV type 16 is the most common in all 
continents, with an estimated point prevalence of 2.6% 
(95% CI: 2.5-2.8) worldwide, and HPV type 18 the 
second most frequently detected type (Clifford et al, 
2005). Regional differences are thought to be related to 
geographical and immunogenetic factors, such as 
defects in cellular immunity through chronic cervical 
inflammation, malnutrition and more recently, HIV 
infection; Type 16 though appears to be less influenced 
by immune impairment than other types (Clifford et al, 
2005).   
Although many women get infected with HPV, most do 
not develop cervical cancer. Several co-factors are 
postulated to influence the disease process. The 
potential co-factors include exogenous factors such as 
tobacco smoking, hormonal contraceptives, and co-
infections with other sexually transmitted infections 
(Munoz et al, 2006). In addition, viral co-factors, such 
specific HPV types, viral load, and viral integration, as 
well as host co-factors such as endogenous hormones, 
genetic factors, and factors related to the immune 
response may variably influence the course of HPV 
infection (Munoz et al, 2006). 
Women with HIV infection have been shown to be more 
likely not only to have a concurrent HPV infection but 
also to have an increased risk for a high grade cervical 
squamous intraepithelial lesion (La Ruche et al, 1998; 
Temmerman et al, 1999; Womack et al, 2000; Baay et al, 
2004; Hawes et al, 2006; Didelot-Rousseau et al, 2006; 
Ngándwe et al, 2007). HPV is the commonest sexually 
transmitted infection, with more than 75% of sexually 
active adults acquiring one or more genotypes in their 
lifetime (Bosch et al, 2008). However, by age 30 years, 
most women clear the infection due to an effective cell-
mediated immune response, and only a small number 
thereafter are diagnosed with a HPV-associated lesion 
(Schiffman, 1992). It is thought that it is through its 
effect on CD4+ cells and regulation of immune 
responses to a variety of antigens that HIV attenuates 
the systemic response to HPV (Palefsky, 2006).  
The prevalence of HIV among adult Kenyan women was 
13% in 2003 with trends reported to have decreased to 
5.1% by 2006 (KDHS, 2003).  The high prevalence of 
HIV may increase the incidence of cervical pre-cancer 
and potentially, of cervical cancer. Gichangi et al (2002), 
however, demonstrated that a two to three-fold 
increase in HIV prevalence did not translate to a 
proportionate increment in incidence of cervical cancer. 
They hypothesized that HIV-infected women die from 
HIV-related opportunistic infections before they 
develop invasive cervical cancer. The mean survival 
time for women with HIV in 2008 was reported to be 5 
years (Yamada et al, 2008) while typically more than 10 
years elapse before the development of cervical cancer 
after HPV infection. Yamada et al (2008) also advanced 
the possibility that sub-clinical cervical cancer may be 
missed in many women dying prematurely from AIDS-
related opportunistic infections. 
This study was carried out to establish whether the co-
infection of HIV and HPV has an influence on HPV 
genotype distribution and on the prevalence and grade 
of cervical neoplasia. 
2. Methodology 
2.1 Study population  
In a population-based study in Tigoni, Kenya, women 
aged 25 to 60 years eligible for cervical cancer 
screening were screened for cervical cancer and HIV 
infection. Inclusion criteria included age between 25 
and 60 years, sexually active but not pregnant, and 
should not have had a hysterectomy or ablation of the 
cervix. Exclusion criteria were prior conization or other 
treatment for cervical neoplasia, mental incompetence, 
and not giving consent to participate.  
The prevalence of cervical neoplasia in some studies 
had shown to be about 10% in HIV negative women and 
more than 29% in HIV positive women (ter Muelun, 
1992). It was expected then that more than 500 women 
would have abnormal smears in this population and 
these would be enrolled for the subsequent studies for 
the description of prevalence and types of HPV in HIV 
positive and negative women. Out of these it was 
conservatively expected that about 60% (Rozeendal et 
al, 2000), would have low grade lesions and these 
would be enrolled for colposcopy and biopsy in the 
evaluation of CIN in HIV positive and HIV negative 
patients. 
Assumptions at recruitment: 
1. That Tigoni District Hospital, being a district public 
hospital, would provide most of the health care 
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services that the local communities would need, 
and was accessible to all age groups, all genders and 
all religions. 
2. That there was no exclusion on the basis of socio-
economic status in service provision by the Tigoni 
District Hospital. 
3. That the study did not specifically select those who 
were immune-compromised by HIV infection.  
4. That there was no exclusion of those screened from 
social networks or women’s groups (an important 
vehicle for recruitment for the study).  
Most women in this peri-rural community belonged to a 
church or women’s group. In previous community 
mobilization activities for health events such as health 
field days, the University of Nairobi’s Centre for Health 
and Behaviour Studies had used the women leaders of 
these groups to get the word out and to send 
invitations. We used the same social networks for 
recruitment and for re-calling those women who 
needed follow-up and did not return for their 
appointment. 
2.2 Investigations 
Informed consent was obtained from the women and a 
pre-tested questionnaire administered to collect socio-
demographic, gynecological history and lifestyle 
information. A gynecological examination was 
performed and a liquid-based cervical sample collected. 
The cervical cytology was reported using the Bethesda 
system 2001 (Solomon et al, 2002). A total of 629 out of 
4,500 women had an abnormal pap smear [Atypical 
squamous cells of undetermined significance (ASCUS)]. 
Over 72% of those with abnormal smear had 
colposcopy and biopsy and their residual liquid-based 
pap smears were further processed for HPV typing. A 
tracer was also engaged to trace women who had 
abnormal cytology and needed colposcopy or were HIV 
positive and did not return for their appointments. 
HPV typing was done on the residual sample by 
polymerase chain reaction (PCR) as described by 
Depuydt et al (2006).  Amplification of β-globin DNA 
was performed as a positive control for the presence of 
amplifiable DNA in the specimens. Testing was done at 
Labo RIATOL, Antwerp, Belgium. All samples were 
subjected to 19 different quantitative PCRs. 
Oligonucleotide primers and probes for PCR detection 
and quantification of HPV 16 E7, 31 E6, 33 L1, 35 E4, 39 
E7, 51 E6, 52 L1, 58 L1, 58 E6 and 67 L1 were selected. 
The viral load of HPV type 16 E7, 18 E7, 31 E6, 33 L1, 33 
E6, 35 E4, 39 E7, 45 E7, 51 E6, 52 L1, 52 E7, 53 E6, 56 
E7, 58 L1, 58 E6, 59 E7, 66 E6 and 68 E7 was 
determined using a TaqMan-based real-time PCR 
analysis. All positive smears and tissue biopsy slides 
were sent to University of Ghent for a second reading as 
a quality control measure. For analysis, the HPV types 
were classified according to oncogenic risk. High risk 
types included 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 
59; Probable high risk (or intermediate risk): 26, 53, 66, 
68, 73, 82; and low risk types: 6, 11, 40, 42, 43, 44, 54, 
61, 70, 72, 81 and CP6108 (Munoz et al, 2006). 
Blood was obtained for HIV testing at the same time at 
which the pap smears were taken. HIV testing was 
performed using enzyme-linked immunosorbent assay 
(ELISA) and all positives confirmed by a second ELISA. 
Blood was drawn for CD4 counts on the return 
appointment if the woman was HIV positive. All those 
who had an abnormal smear were referred for 
colposcopy and biopsy. The biopsy results for those 
who returned for that appointment are included in the 
analysis. 
2.3 Statistical Analysis  
Data was entered into SPSS version 11.5 and analyzed. 
Continuous variables were summarized as means and 
standard deviations, and categorical variables were 
summarized into frequencies and percentages. Data 
analysis was descriptive and categorical for cervical 
neoplasia and HPV/HIV co-infection, as well as 
categorical for HPV types in cervical neoplasia for both 
HIV positive and negative women. Odds ratios were 
calculated for HPV and HIV infection in women with 
cervical neoplasia. Levels of significance were set at 
0.05. 
2.4 Ethical Considerations 
Ethical approval to carry out this study was granted by 
the Kenyatta National Hospital/University of Nairobi 
Ethics and Research Committee (KNH/UON Study 
approval No: P144/12/2003).  
Pap smears and blood samples were obtained after 
written, informed consent. The participants received all 
their pap smear and HIV results after post-test 
counseling, but were informed that the results of HPV 
typing would not be availed to them since, at the time, 
they had no clinical utility. 
3. Results  
The demographic characteristics of the women with 
HPV results are shown in Table 1. Out of 629 samples 
for which HPV typing was done, 438 had a HPV result of 
which 32.7% were positive. The positive rate was 
highest in the youngest age group (25-29 years) at 
28.6%, dipped marginally to 26.4% in the next age 
group and then increased, also marginally to 27.1% in 
the age group 35-39. Thereafter, it decreased with age, 
although there was a small peak in the 50-54 years.  
Factors such as age, contraceptive use and HIV status 
were significant in HPV infection (p<0.05), while being 
currently post-partum or menopausal, age at first 
intercourse, number of sexual partners either lifetime 
or recent and parity were not (Table 2, Supporting 
Information). 
HPV genotyping results were initially grouped 
according to HPV risk group and cytologic diagnostic 
category as shown in Table 3 (Supporting Information). 
Of the total 324 pap smears reported as normal 
cytology, 67 (20.7%) were HPV positive, 14.2% were 
High Risk (HR)-HPV positive, the remainder, 6.5% were 
Intermediate HPV-type positive, and 79.3% were 
negative HPV. The HR-HPV types were dominant in all 
diagnostic categories but HR-HPV and intermediate 
HPV types had similar positive rates in LSIL categories. 
LR-HPV types were uncommon in this group. When 
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presence of any HPV was analyzed according to cervical 
biopsy result, 75.6% (31) of those who had a normal 
biopsy result were negative, and 34% (12) of those 
reported as having a Cervical intraepithelial neoplasm 
grade III (CIN III) or greater were positive (Table 4, 
Supporting Information). The association between the 
HPV status and the diagnostic categories was significant 
(p<0.0001). 
Table 1: Unadjusted analysis for HPV infection 
Variable 
Total 
(n=438)  
HPV Status 
O.R (95% C.I) p-value Positive 
(n=140) (%) 
Negative 
(n=298) (%) 
Age in years      
25-29 
30-34 
35-39 
40-44 
45-49 
50-54 
55+ 
108 
96 
103 
62 
37 
20 
12 
40 (28.6) 
37 (26.4) 
38 (27.1) 
14 (10.0) 
3 (2.1) 
5 (3.6) 
3 (2.1) 
68 (22.8) 
59 (19.8) 
65 (21.8) 
48 (16.1) 
34 (11.4) 
15 (5.0) 
9 (3.0) 
1 
1.07 (0.58-1.96) 
0.99 (0.55-1.81) 
0.50 (0.23-1.07) 
0.15 (0.03-0.56) 
0.57 (0.17-1.84) 
0.57 (0.11-2.48) 
 
0.939 
0.904 
0.075 
0.001 
0.435 
0.534 
Gynecologic status       
Menopause 39 8 (5.7) 31 (10.4) 0.52 (0.21-1.23) 0.108 
History of contraceptive use n=  419 n=136  n=283    
None 
Current contraceptive 
IUD 
Hormonal (Oral) 
DMPA  
Other 
183 
 
37 
51 
56 
92 
76 
 
6 
20 
19 
15 
107 
 
31 
31 
37 
77 
2.08 (1.35-3.22) 
 
0.52 (0.18-1.40) 
2.34 (1.14-4.77) 
1.74 (0.86-3.51) 
0.43 (0.21-0.86) 
<0.001 
 
0.232 
0.018 
0.134 
0.016 
HIV test 
Positive 
 
114 
 
77 
 
37 
 
8.62 (5.20-14.34) 
 
<0.001 
Parity 
Median range 
 
 
 
3(0-9) 
 
3(0-9) 
 
 
0.301 
 
Figure 1: Distribution of HPV risk type and cervical lesion 
 
 
0
1
2
3
4
5
6
7
Norm CIN CIN CIN III 
P
e
rc
e
n
ta
g
e
 o
f 
 
high 
 
intermediat
 
low risk 
Muchiri et al. Afr. J. Pharmacol. Ther. 2012. 1(3): 97-105 
 
A KeSoBAP Publication ©2012. All rights reserved.  ISSN 2303-9841 
Table 6: HPV prevalence and risk status by HIV status among women in Tigoni (n=438) 
HPV 
HIV STATUS 
P-value Population 
(n=438) 
Sero-negative 
(n=324) 
Sero-positive 
(n=114) 
Status  
- negative 
-  positive 
298(68.0) 
140(32.0) 
261(80.6) 
63(19.4) 
37(32.5) 
77(67.5) 
 
<0.0001 
Risk Status  
       -     High 
- Intermediate 
- Low 
 
91(20.8) 
44(10.0) 
5(1.1) 
 
48(14.8) 
14(4.3) 
1(0.3) 
 
43(37.7) 
30(26.3) 
4(3.5) 
 
 
<0.0001 
HPV Types (HPV present n=140)    
HPV 16 27(6.2) 11(3.4) 16(14.0) 0.629 
HPV 18 8(1.8) 3(0.9) 5(4.4) 0.661 
HPV 31 17(3.9) 8(2.5) 9(7.9) 0.856 
HPV 33 13(3.0) 3(0.9) 10(8.8) 0.095 
HPV 35 18(4.1) 6(1.9) 12(10.5) 0.287 
HPV 39 22(5.0) 7(2.2) 15(13.2) 0.176 
HPV 45 14(3.2) 3(0.9) 11(9.6) 0.062 
HPV 51 13(3.0) 6(1.9) 7(6.1) 0.930 
HPV 53* 27(6.2) 7(2.2) 20(17.5) 0.027 
HPV 56 25(5.7) 8(2.5) 17(14.9) 0.149 
HPV 59 11(2.5) 7(2.2) 4(3.5) 0.196 
HPV 66* 14(10.0) 4(6.3) 10(13.0) 0.193 
HPV 68* 10(7.1) 3(4.8) 7(9.1) 0.322 
* Intermediate risk (IR)-HPV types 
 
ASCUS/AGUS – Atypical squamous cells of undetermined significance/Atypical glandular cells, LSIL – Low grade 
squamous intra-epithelial lesions, HSIL – High grade squamous intra-epithelial lesions 
Figure 2: HPV type frequency and cervical neoplasia grade 
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The results of HPV oncogenic risk categories and the 
cervical biopsy results are presented in Table 5 
(Supporting Information). HR-HPV types were found in 
all biopsy diagnostic categories in the 76 cases that had 
a tissue biopsy, and were the dominant types in this 
group. Intermediate risk and LR-HPV types were much 
lower. 
The individual HPV types and their distribution by HIV 
status is shown in Table 6 and Figure 1. A total of 77 
(67.5%) were HIV+/HPV+; 261 (80.6%) were HIV-
/HPV-; 63 (19.4%) were HIV-/HPV+; and 37  (32.5%) 
were HIV+/HPV-. The association between HPV and HIV 
was significant. The HPV type distribution however, did 
not seem to be influenced by the HIV status (p>0.05) 
(Table 6) in the 140 cases that were positive for HPV.  
When compared with HIV as a risk factor for HPV 
infection, 37 (32.5%) were HPV-/HIV+,  63 (19.4%) 
were HPV+/HIV-, 77 (67.5%) were HPV+/HPV+ 
(p<0.0001); HR-HPV+/HIV+ were 43 (37.7%), IR-
HPV+/HIV+ 30 (26.3%), and LR-HPV+/HIV+ 4 (3.5%), 
(p<0.0001). High risk (HR)-types were the more 
frequent across all positive samples. Type 16 was the 
most frequent type in both normal and abnormal 
cytology samples, although it had the highest frequency 
in high-grade cervical lesions. The 5 most frequent HPV 
types were 16, 56, 53, 35, 39 with 15%, 10.5%, 9.3%, 
7.9%, and 7.9% respectively. Type 18 had an overall 
frequency of 1.3%. 
The ten most frequent HPV types in normal, squamous 
intra-epithelial lesions and ASCUS/AGC are represented 
graphically in Figure 2. Pap smears reported as normal 
had the broadest spectrum of HPV types, of which 31 
was the most frequent, followed by 53 and 56; in LSILs, 
HPV types 16, 31, 53 and 56 had similar frequencies, 
and 59 and 39 were about half frequent; in HSIL, HPV 
type 16 was the most frequent, followed by similar 
frequencies for types 31, 35, 45 and 51. Three types 
were found in the few cases of ASCUS/AGC, type 56 
being the most frequent, and followed by 16 and 59. 
There was no type 18 or the related type 45 found in 
ASCUS/AGC, which was only found in normal pap 
smears. 
When HPV type 16 was analyzed for cervical grade of 
disease, the frequency increased with the severity of 
cervical lesion (Figure 3). It was also present in normal 
smears. 
The CD4 lymphocyte counts for those who were HIV 
positive are shown in Table 7 (Supporting Information) 
and the distribution across clinical utility categories in 
women with abnormal cytology in Figure 4. The rates 
of HPV infection and abnormal cytology increased as 
CD4+ cell counts decreased as did the number of HPV 
types, especially the HR and LR types involved in the 
infection. HIV negative women were included as 
controls. 
4. Discussion 
The results of this study show a high prevalence of HPV 
infection in cervical samples at a given point in time of 
32.7% in a population of women with a high HIV 
prevalence of 14.2%.  The age-adjusted global figure of 
HPV DNA in women with normal cytology in large meta-
analysis studies was 10.5% and 31.6% for Eastern 
Africa (Bosch et al, 2006) in which PCR-based assays 
were used for HPV DNA detection in cervical cells. 
Prevalence of HPV in women with cervical lesions is 
generally reported in the range of 50-85% (Bosch et al, 
2006). In our study population, the HPV prevalence in 
samples with abnormal cytology was 52%, and 80% in 
those who had biopsy confirmed CIN III or greater.  The 
prevalence of HPV is high in young women in this study 
as expected, where prevalence mirrors incidence, 
declining with age, as women clear the infection. There 
was a small increase in the age group 50-54 years. A 
similar trend has been previously documented by Bosch 
et al (2006) who raised several possibilities for the 
second increase: new HPV infections acquired by 
middle-age women due to changes in sexual behaviour, 
reactivation of latent infection following immune 
senescence, and/or a cohort effect translating high 
exposure throughout their lifetime in elderly 
populations. Follow-up and behavioral studies have 
reported a high rate of new sexual partners among the 
40 years and older in developed countries (Munoz et al, 
2004; Wellings et al, 2006) and the difference of close to 
ten years in the age groups between Europe and the 
United States for the second peak was thought to be 
suggestive of a behavioral factor rather than a biological 
factor linked to menopause or immune senescence 
(Bosch et al, 2006). Bosch et al (2006) also raised the 
concept of latency of HPV infection as best 
demonstrated in recurrent respiratory papillomatosis 
(RRP) in which LR-HPV types 6/11 keep recurring from 
apparently normal tissue in the absence of obvious 
external infection.  
Sexual history by age at first intercourse, number of 
lifetime and recent sexual partners did not seem to 
influence the prevalence of HPV infection in this study 
group. Majority of women reported having had only one 
lifetime sexual partner, consistent with other large 
studies that examined population distributions in Kenya 
and some developing countries by age and sex and 
number of sexual partners in the past year from 15 to 
45 years (Wellings et al, 2006).  Contraceptive use was 
significant factor for HPV infection in this study group 
(p<0.001), and even though the numbers are small, this 
finding is consistent with findings in an IARC 
monograph classifying hormonal contraceptives as 
carcinogenic to the cervix and increased risk for women 
who tested positive for high risk HPV-DNA and for CIN 
3/carcinoma in situ (Smith et al, 2007). The 
hypothesized mechanism through which hormonal 
contraceptives may act as a cofactor for cervical 
neoplasia is that estrogens and progestagens enhance 
HPV gene-expression in the cervix through 
progesterone-receptor mechanisms and hormone-
response elements in the viral genome (Bosch et al, 
2006). 
HR-HPV types, and in particular HPV type 16, were the 
most frequent across all diagnostic categories. The 
prevalence in HSIL was lower than the reported 85% in 
cross-sectional studies of the natural history of cervical 
cancer supportive of the contribution of HPV in HSIL 
(thought to represent the true morphological precursor 
of invasive cervical cancer) (Clifford et al, 2005). There 
is substantial variability however, in attributable risk of 
HPV in the various studies of the meta-analysis between 
CIN 2 and CIN 3; this is thought to be probably due to 
variations in the quality of specimens tested and the 
HPV DNA assays used (Clifford et al, 2005).  
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Figure 3: Distribution of HPV 16 by cervical lesion grade 
Figure 4: Comparison of HPV infection and abnormal cytology in HIV sero-negative and HIV-
seropositive women versus CD4+ counts (cells/µl) 
The most frequent HPV types in this study in women 
with normal cytology in descending order were: HPV-
31, -56, -53, -59, -16, -18, -39, -51, -58, -45, and -35, in 
LSIL in descending order were HPV-16, -31, -51, -56, -
59, and -39; in HSIL were HPV-16, -51, -45, -35, and -31; 
and in ASCUS/AGC HPV-56, -16 and -59. In comparison 
a comprehensive meta-analysis of 53 studies published 
up to 2006 in women with and without cervical lesions 
showed the following HPV types in order of decreasing 
prevalence: in  women without cervical abnormality: 
HPV-16, -42, -58, -31, -18, -56, -81, -35, -33, -45, and -
52; in LSIL: HPV-16, -31, -51, -53,  -56, -52, -18, -66, and 
-58 and  for HSIL: HPV-16, -31, - 58, -18, -33, -52, -35, -
51, -56, -45, -39, -66, and 6 [Smith et al 2007]; with 
women in Africa being less likely to be infected with 
HPV 16 than other HR-HPV and LR-HPV types than their 
counterparts in Europe, although more likely to be 
infected with other HR-HPV and LR-HPV types [Clifford 
et al 2005].   
No meta-analysis on HPV type-specific prevalence 
among women with ASCUS currently exists, probably 
because the diagnosis of ASCUS, unlike that of LSIL, is 
less well standardized given the wide variability in 
intra- and inter-observer definition, and HPV positivity 
varies greatly in published studies (Clifford et al, 2006). 
There were close similarities in the most frequent types, 
except for the low frequency of HPV type 18 and 45 in 
cases with abnormal cervical cytology in our series. In a 
study in Thika, Kenya, Ngugi et al (2011) found similar 
HPV type distribution with highest frequency of HPV 
type 16, and type 18 being less common than 
internationally reported. The intermediate types were 
also less frequent in our population than is reported in 
meta-analysis studies. 
The results indicated an increase in HPV and abnormal 
cervical lesions as CD4+ cells decreased, as has been 
reported elsewhere (Yamada et al, 2008); the 
prevalence of oral, anal and cervical HPV infection in 
HIV positive compared to HIV negative individuals 
increases with progressively lower CD4+ cell counts, as 
does the incidence of high-grade intraepithelial lesions 
(Palefsky, 2006). 
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5. Conclusion   
HPV infection rate was high in this population with a 
high HIV prevalence. Age, contraceptive use, and HIV 
infection were significant factors in HPV infection with 
65.5% of cases being both HPV and HIV infected. Over 
77% of those individuals who had a CIN III or greater 
were HPV positive. HR-HPV types were found across all 
diagnostic categories in the cases that had a cervical 
tissue biopsy with HPV type 16 being the most 
dominant type, particularly in high grade lesions. Types 
18 and 45, some of the more frequently reported 
elsewhere in women with cervical lesions, were absent 
in the abnormal cases. The rates of HPV infection and 
abnormal cytology increased as CD4+ cell counts 
decreased, as did the number of HPV types involved in 
the infection. HPV type distribution in this population 
has implications for HPV-DNA based diagnostics and 
future vaccine developments for the region. 
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Table 2: HPV infection status, cervical biopsy results and sexual history 
 
Variable 
HPV Status  
O.R (95% C.I) 
 
p-value Positive Negative 
Age at first intercourse     
<18 
18+ 
23 
36 
42 
76 
1.16 (0.58-2.31) 
1 
0.783 
 
Number of lifetime sexual partners     
1 
2+ 
15 
44 
51 
67 
1 
2.23 (1.06-4.73) 
 
0.032 
Number of recent sexual partners     
1 
2+ 
48 
5 
101 
7 
1 
1.50 (0.39-5.64) 
 
0.532 
Biopsy Results 
Normal 
CIN I 
CIN II 
CIN III/CIS/ISC 
 
9 
8 
6 
12 
 
31 
6 
1 
3 
 
1 
4.59 (1.07-20.66) 
20.7 (1.95-521.1) 
13.8 (2.71-80.09) 
 
 
0.023 
0.003NS 
0.003NS 
 
Variable 
HIV Status  
O.R (95% C.I) 
 
p-value Positive Negative 
Risk Status     
High 
Intermediate 
Low 
43 
30 
4 
48 
14 
1 
0.22 (0.01-2.27) 
0.54 (0.02-6.06) 
1 
0.199 
1.000 
 
NS – not significant; CIN – cervical intraepithelial neoplasia; CIS – carcinoma in situ; ISC – invasive squamous carcinoma 
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Table 3: Distribution of HPV risk group and cytologic diagnostic category (n=443) 
HPV 
Cytology 
Normal 
n (%) 
ASCUS/AGC 
n (%) 
LSIL 
n (%) 
HSIL/AIS/Squamous 
cell carcinoma 
n (%) 
Positive      
HR –HPV 
IR-HPV 
LR-HPV                                                                           
 
46 (14.2) 
21 (6.5) 
0 (.0) 
 
10 (25.0) 
3 (7.5) 
1 (2.5) 
 
15 (34.1) 
15 (34.1) 
2 (4.5) 
 
20 (57.1) 
5 (14.3) 
2 (5.7) 
Sub-total positive 67 (20.7) 14 (35) 32 (72.7) 27 (77.1) 
Negative 257 (79.3) 26 (65.0) 12 (27.3) 8 (22.9) 
Total 324 (73.1) 40 (9.0) 44 (9.9) 35 (7.9) 
ASCUS – atypical squamous cells of undetermined significance; AGC – atypical glandular cells; AIS – adenocarcinoma in situ; LSIL – 
Low grade squamous intraepithelial lesion; HSIL – High grade squamous intraepithelial lesion; HR – High risk; IR – intermediate risk; 
LR – low risk 
 
 
 
Table 4: Un-adjusted analysis for HPV infection by cervical biopsy result (n=76) 
  Characteristic 
HPV STATUS 
P-value Negative 
(n=41/76) 
Positive 
(n=35/76) 
Cervical biopsy  Results  
- Normal 
- CIN I  
- CIN II 
- CIN III /CIS/ISC 
 
31 (75.6) 
6 (14.6) 
1 (2.4) 
3 (7.3) 
 
9 (25.7) 
8 (22.9) 
6 (17.1) 
12 (34.3) 
<0.0001 
The percentages were calculated down the column 
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Table 5: Comparison of oncogenic HPV types with cervical lesion grade (n=76) 
HPV 
Population 
(n=76)(%) 
Cervical lesion grade 
Normal 
(n=40)(%) 
CIN I 
(n=14)(%) 
CIN II 
(n=7)(%) 
CIN III /CIS/ISC 
(n=15)(%) 
Status  
- negative 
-  positive 
 
41 (53.9) 
35 (46.1) 
 
31 (77.5) 
9 (22.5) 
 
6 (42.9) 
8 (57.1) 
 
1 (14.3) 
6 (85.7) 
 
3 (20.0) 
12 (80.0) 
Risk Status  
- High 
- Intermediate 
- Low 
 
22 (62.9) 
10 (28.6) 
3 (8.6) 
 
6 (66.7) 
3 (33.3) 
0 (.0) 
 
5 (62.5) 
2 (25.0) 
1 (12.5) 
 
3 (50.0) 
2 (33.3) 
1(16.7) 
 
8 (66.7) 
3 (25.0) 
1 (8.3) 
Types 
HPV 16 
HPV 18 
HPV 31 
HPV 33 
HPV 35 
HPV 39 
HPV 45 
HPV 51 
HPV 53 
HPV 56 
HPV 59 
HPV 66 
HPV 68 
12 (34.3) 
1 (2.9) 
2 (5.7) 
1 (2.9) 
6 (17.1) 
6 (17.1) 
3 (8.6) 
3 (8.6) 
7 (20.0) 
8 (22.9) 
2 (5.7) 
3 (8.6) 
3 (8.6) 
1 (11.1) 
0 (0.0) 
1 (11.1) 
0 (0.0) 
0 (0.0) 
1 (11.1) 
0 (0.0) 
1 (11.1) 
2 (22.2) 
3 (33.3) 
2 (22.2) 
0 (0.0) 
1 (11.1) 
2 (25.0) 
1 (12.5) 
0 (0.0) 
0 (0.0) 
4 (50.0) 
0 (0.0) 
2 (25.0) 
1 (12.5) 
2 (25.0) 
4 (50.0) 
0 (0.0) 
1 (12.5) 
0 (0.0) 
2 (33.3) 
0 (0.0) 
1 (16.7) 
1 (16.7) 
1 (16.7) 
3 (50.0) 
0 (0.0) 
0 (0.0) 
1 (16.7) 
0 (0.0) 
0 (0.0) 
2 (33.3) 
0 (0.0) 
7 (58.3) 
0 (0.0) 
0 (0.0) 
0 (0.0) 
1 (14.3) 
2 (28.6) 
1 (14.3) 
1 (14.3) 
2 (28.6) 
1 (14.3) 
0 (0.0) 
0 (0.0) 
2 (28.6) 
Intermediate risk-HPV (IR-HPV) types are in bold 
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Table 7: HPV prevalence and risk status in HIV positive women stratified by CD4 levels 
HPV  Prevalence  
Population 
CD4 levels 
<200 200-350 >350 
70 (73.7%) 32 (78.0%) 18 (85.7%) 20 (60.6%) 
Risk Status  
- High 
- Intermediate 
- Low 
 
42 (44.2%) 
23 (24.2%) 
5 (5.3%) 
 
18 (43.9%) 
10 (24.4%) 
4 (9.8%) 
 
14 (66.7%) 
3 (14.3%) 
1 (4.8%) 
 
10 (30.3%) 
10 (30.3%) 
0 (0.0%) 
HPV Types     
HPV 16 16 (16.8%) 9 (22.0%) 4 (19.0%) 3 (9.1%) 
HPV 18 4 (4.2%) 3 (7.3%) 1 (4.8%) 0 (0.0%) 
HPV 31 8 (8.4%) 5 (12.2%) 3 (14.3%) 0 (0.0%) 
HPV 33 8 (8.4%) 6 (14.6%) 0 (0.0%) 2 (6.1%) 
HPV 35 13 (13.7%) 10 (24.4%) 0 (0.0%) 3 (9.1%) 
HPV 39 14 (14.7%) 6 (14.6%) 2 (9.5%) 6 (18.2%) 
HPV 45 10 (10.5%) 7 (17.1%) 3 (14.3%) 0 (0.0%) 
HPV 51 7 (7.4%) 5 (12.2%) 2 (9.5%) 0 (0.0%) 
HPV 53* 15 (15.8%) 7 (17.1%) 2 (9.5%) 6 (18.2%) 
HPV 56 18 (18.9%) 10 (24.4%) 5 (23.8%) 3 (9.1%) 
HPV 59 4 (4.2%) 3 (7.3%) 0 (0.0%) 1 (3.0%) 
HPV 66* 8 (8.4%) 6 (14.6%) 1 (4.8%) 1 (3.0%) 
HPV 68* 6 (6.3%) 3 (7.3%) 0 (0.0%) 3 (9.1%) 
* Intermediate risk (IR)-HPV types 
 
 
 
 
 
